South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...

Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar ...

South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three ...

Celltrion plans to buy back 100 billion won ($69 million) in stocks, purchasing 554,632 shares starting Thursday.

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...

Celltrion, a major Korean biopharmaceutical firm, said Wednesday it will buy back 100 billion won ($69 million) worth of its ...

Celltrion announces 100 billion won share buyback, starts market purchase tomorrow Celltrion to start market share buyback ...

Celltrion’s two biosimilar treatments for treating osteoporosis and preventing bone metastasis complications in cancer ...

Celltrion is aggressively pursuing global clinical trials for a new antibody-drug conjugate (ADC) cancer treatment. Celltrion submitted an investigational new drug (IND) application to the U.S ...

The US Food and Drug Administration (FDA) has granted approval for Celltrion's Avtozma (tocilizumab-anoh) in both intravenous and subcutaneous formulations as an Actemra biosimilar for treating ...

Ra­dio­phar­ma­ceu­ti­cals biotech Ad­van­Cell has pulled to­geth­er a $112 mil­lion Se­ries C about two years af­ter its much small­er Se­ries B of … ...